Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of Autologous Cytokine Induced Killer (CIK) Cells Infusion as an Adjuvant Therapy in Post Resection Hepatocellular Carcinoma (HCC) Patients

NCT07709299 is registered in ClinicalTrials.gov with Royan Institute as lead sponsor.

NCT NCT07709299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07709299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of Autologous Cytokine Induced Killer (CIK) Cells Infusion as an Adjuvant Therapy in Post Resection Hepatocellular Carcinoma (HCC) Patients
Lead sponsor
Royan Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
July 31, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)